| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT00014222 |
| P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
| P767 | contributor to the creative work or subject | North Central Cancer Treatment Group | Q7054727 |
| P17 | country | United States of America | Q30 |
| Canada | Q16 | ||
| P582 | end time | 2006-10-01 | |
| P4135 | maximum age | 60 | |
| P1132 | number of participants | 2104 | |
| P4844 | research intervention | epoetin alfa | Q5383794 |
| Caelyx | Q29004943 | ||
| fluorouracil | Q238512 | ||
| (RS)-cyclophosphamide | Q408524 | ||
| paclitaxel | Q423762 | ||
| doxorubicin | Q18936 | ||
| P6153 | research site | University of Rochester | Q149990 |
| University of Florida | Q501758 | ||
| Royal Victoria Hospital | Q84238284 | ||
| McMaster University | Q632891 | ||
| Saint Louis University | Q734774 | ||
| Scripps Research | Q793867 | ||
| University of Toronto | Q180865 | ||
| Mount Sinai Hospital | Q1476505 | ||
| Hôpital Charles-LeMoyne | Q2377754 | ||
| St. Michael's Hospital | Q3145237 | ||
| BC Cancer Agency | Q4835275 | ||
| Staten Island University Hospital | Q7604005 | ||
| Duke University Medical Center | Q30279912 | ||
| CancerCare Manitoba | Q30282110 | ||
| University of Chicago | Q131252 | ||
| P580 | start time | 2000-12-01 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Phase III Adjuvant Trial Of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery For Node Positive Or High Risk Node Negative Breast Cancer |
Search more.